A Phase I Study of Nivolumab in Combination With Ipilimumab for the Treatment of Patients With High Risk or Refractory/Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cyclophosphamide; Tacrolimus
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
Most Recent Events
- 12 Dec 2024 Status changed from active, no longer recruiting to completed.
- 08 May 2024 Planned End Date changed from 31 Mar 2024 to 31 Mar 2026.
- 08 May 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2026.